Searched for
LUPIN PHARMACEUTICALS
Lupin gets USFDA approval for Modafinil tablets to treat excessive sleepinessPharmaceutical major Lupin announced its USFDA approval for Modafinil tablets. These tablets are used to treat excessive sleepiness in adul...- When volatility rises, will you panic or buy? Depends on the watchlist you build now: 5 large-cap stocks with upside potential of up to 32%Another worry has emerged for the markets, and it will drive the narrative in the short term. As usual, it comes from the US. The US Fed ha...
- Lupin share falls 2%; Citi downgrades to Sell, cuts target price to Rs 2,050Lupin shares fell after Citi downgraded the stock to ‘Sell’ and cut its target price to Rs 2,050. The brokerage expects weaker US base-busi...
- Medical devices industry needs to focus more on local value addition: Pharma SecyThe medical devices sector must increase local value addition and component manufacturing. Government officials are open to industry sugges...
- Delhi High Court rules in favour of Dr Reddy's Labs in trademark row with RazentaThe Delhi High Court ordered the removal of Razenta Pharmaceuticals' Daplogin trademark. This decision came as the mark was deemed deceptiv...
- Capitalmind Flexi Cap Fund exits Vedanta and 10 others; adds 9 stocksDeepak Shenoy-backed Capitalmind Flexi Cap Fund exited 11 stocks, including Vedanta and Vedanta Oil and Gas, and added nine stocks, includi...
- India's pharma sector must shift from cost competitiveness to innovation, global quality: ExpertsFor the growth of India's pharmaceutical sector, prioritizing innovation and advanced manufacturing is essential. Experts indicate that inc...
- Lupin shares in focus after USFDA nod for drug to treat excessive daytime sleepinessLupin received USFDA approval for generic Pitolisant Tablets, strengthening its US portfolio and specialty generics presence. Shares remain...
- Picking the right pharma stock is getting harder; so pick a portfolio: 20 stocks with -23% to +22% downside to upside potentialFor Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...
- ET Health Conclave 2026: Healthcare leaders reimagine the future of medicine through innovation, prevention and technologyThe ET Health Conclave 2026 celebrated healthcare professionals and institutions. Leaders shared insights on healthcare infrastructure and ...
- Lupin launches generic Sugammadex injection in USLupin Limited announced the launch of its Sugammadex Injection in the United States. This follows approval from the US Food and Drug Admini...
- BDR Pharmaceuticals eyes controlling stake in Acme FormulationPAG acquired a controlling stake in Acme Formulation for $145 million (?1,054 crore) through its PAG Asia III buyout fund in 2021. Founder ...
- Tariff on generic drugs: Loud announcement, little consequence? 7 pharma stocks with upside potential of up to 31%The threat of a US tariff on Indian pharma is no longer a vague fear; or at least that is what President Trump wants us to believe. There i...
- Pharma stocks slide as Trump's 100% generic drug tariff plan spooks investorsIndian drug shares declined Wednesday following US President Trump's tariff announcement. These proposed tariffs will significantly impact ...
- Domestic formulations, chronic therapies to drive Pharma Q1; US generics remain dragThe healthcare sector anticipates strong growth in domestic formulations and emerging markets. Companies with less US generics dependence w...
- Explained: What Donald Trump's up to 200% pharma tariffs mean for Indian investorsDonald Trump's announcement of tariffs of up to 200% on pharmaceutical imports triggered a selloff in Indian pharma stocks. However, analys...
- 200% Trump tariff shock? India’s cheap pills may still beat US rivalsUS President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could put pressure on India's pharmaceutical expor...
- Trump's Generic Drug Tariffs Explained: What it means for Indian pharma before the 200% stormTrump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufactur...
- Trump announces new generic drugs tariff plan: No tariffs for 2 years, then 100%, and then 200%For Indian exporters, the two-year tariff-free period offers additional time to reassess supply chains and investment plans. While the imme...
- Sun Pharma, Cipla & other pharma stocks shed over 2% as Trump announces up to 200% tariffs on generic drugs from 2028Pharma stocks, including Sun Pharma, Cipla, Lupin and Dr Reddy's, fell up to 2.5% after US President Donald Trump announced a phased tariff...
Load More
